We are proud to have screened and randomized the first participant in the world for many studies. Below are a few examples:
- First patient enrolled out of 388 sites in 42 countries for a landmark cardiovascular outcomes trial, requiring highly-specific cardiovascular events and elevated Lp(a). Our Principal Investigator co-authored the results of the phase 2 study published in the New England Journal of Medicine.
- First patient enrolled in the US for an extremely-difficult-to-find patient population with Severe Hypertriglyceridemia.
- First patient dosed in ultra-rare disease trial